The exposure of single breast carcinoma cells to SSP is accompanied by a transient activation of the canonical MAPK/ERK1/2 pathway, which could be abolished in the presence of the MEK inhibitor U0126 (Figure 4). The gene discussed is MAPK3; the disease is breast carcinoma.